GLAXO Stock Overview
Manufactures, distributes, and trades in pharmaceuticals in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
GlaxoSmithKline Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,698.35 |
| 52 Week High | ₹3,088.00 |
| 52 Week Low | ₹1,385.05 |
| Beta | 0.23 |
| 11 Month Change | -6.70% |
| 3 Month Change | 6.33% |
| 1 Year Change | 73.44% |
| 33 Year Change | 78.77% |
| 5 Year Change | 90.09% |
| Change since IPO | 1,093.56% |
Recent News & Updates
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Recent updates
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?
Jul 07Shareholder Returns
| GLAXO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.7% | -1.1% | 1.2% |
| 1Y | 73.4% | 57.4% | 41.4% |
Return vs Industry: GLAXO exceeded the Indian Pharmaceuticals industry which returned 57.4% over the past year.
Return vs Market: GLAXO exceeded the Indian Market which returned 41.4% over the past year.
Price Volatility
| GLAXO volatility | |
|---|---|
| GLAXO Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: GLAXO has not had significant price volatility in the past 3 months.
Volatility Over Time: GLAXO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 3,211 | Bhushan Akshikar | india-pharma.gsk.com |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease.
GlaxoSmithKline Pharmaceuticals Limited Fundamentals Summary
| GLAXO fundamental statistics | |
|---|---|
| Market cap | ₹473.52b |
| Earnings (TTM) | ₹6.40b |
| Revenue (TTM) | ₹35.07b |
71.4x
P/E Ratio13.0x
P/S RatioIs GLAXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAXO income statement (TTM) | |
|---|---|
| Revenue | ₹35.07b |
| Cost of Revenue | ₹13.54b |
| Gross Profit | ₹21.52b |
| Other Expenses | ₹15.12b |
| Earnings | ₹6.40b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.78 |
| Gross Margin | 61.38% |
| Net Profit Margin | 18.25% |
| Debt/Equity Ratio | 1.1% |
How did GLAXO perform over the long term?
See historical performance and comparison